Sanofi notes ‘negative buzz’ around vaccines as profit beats forecasts
By Bhanvi Satija LONDON (Reuters) -Sanofi reported stronger than expected third-quarter profit on Friday, boosted by demand for blockbuster asthma drug Dupixent, even as the French drugmaker flagged lower vaccination rates partly due to a “negative buzz” around vaccines. Sales of Sanofi’s flu and COVID-19 vaccines dropped 16.8%, hit by pricing pressure in Germany and …
Sanofi notes ‘negative buzz’ around vaccines as profit beats forecasts Read More »










